Search results for ''
Talk at the Annual Conference of Autophagy DRIVE Consortium
Benoît de Chassey gave a talk entitled: “From Virus-Host Interactomes To Drug Discovery” at the Annual Conference of Autophagy DRIVE Consortium (Driving next generation autophagy researchers towards translation) coordinated by Pr Fulvio Reggiori.
ENYO Pharma selected to take part in the French Tech 120 FT120 program
ENYO Pharma has been selected to take part in the French Tech 120 #FT120 program for the second consecutive year. We will thus benefit from specific guidance and visibility. Created by the French government, this program offers support to French scaleups with the potential to become global technology leaders.
https://lafrenchtech.com/en/how-france-helps-startups/ft120/
Immunotherapies & Innovations for Infectious Diseases Congress 2020
December 9-10, 2020
Digital Edition
ENYO will attend the 4th edition of I4ID congress. The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach.
New publication : A new class of molecule targeting the NEET family of proteins
ENYO is proud to share international collaborative study showing the development of MITO-C (one compound of EYP002 series) a new class of molecule targeting the
NEET family of protein. This work co-led by Etienne Morel (INEM, Paris, France) and Benoît de Chassey (ENYO Pharma, Lyon France) and sponsored by ENYO Pharma nicely shows that MITO-C (one compound of EYP002 series) modulates mitochondria morphogenesis and stabilizes ER-Mitochondria contact sites. This seminal fundamental results opens potential indications that go beyond infectious diseases e.g.
Vonafexor accepted as the generic name for EYP001 by the WHO
We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001.
Latest Press Release 